Abstract
We studied 174 consecutive patients with relapsed refractory multiple myeloma (MM) enrolled on a phase II clinical trial of pomalidomide plus low-dose dexamethasone at Mayo Clinic. Extramedullary disease (EMD) was present at the time of trial entry in 7.5% (13 of 174 patients). The rate of EMD in the first 3 years following diagnosis of MM was 3%. The response of EMD to pomalidomide plus low-dose dexamethasone included two complete and two partial responses among the 13 patients (response rate, 31%). Overall survival measured from trial entry was significantly shorter for patients with treatment-emergent EMD compared with those who did not have EMD, (median 16 months versus not reached, P0.002).
Original language | English (US) |
---|---|
Pages (from-to) | 906-908 |
Number of pages | 3 |
Journal | Leukemia |
Volume | 25 |
Issue number | 6 |
DOIs | |
State | Published - Jun 2011 |
Keywords
- extramedullary
- myeloma
- pomalidomide
ASJC Scopus subject areas
- Hematology
- Oncology
- Cancer Research